Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a...

Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System -- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solutionof silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has...

Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints -- Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 -- Sienna continues to advance robust...